Up in smoke? Vaping on the edge of banishment

Industry Insight
Jul.13.2022

The U.S. Food and Drug Administration (FDA) has paused a ban on the sale of Juul Labs’ e-cigarettes, saying it requires an additional review of the company’s marketing application.

 

This pause follows a federal appeals court’s decision a few weeks ago to stay — i.e. temporarily freeze — the FDA’s ban, following an appeal from Juul requesting an emergency review of the FDA’s order.

 

But the once-thriving company isn’t out of the woods just yet: The FDA has only paused the ban for reevaluation. It has not rescinded it.

 

Juul has always been in the spotlight, in part because of its prominent placement atop the e-cigarette chain, but with the company facing a potential demise, it could be the first casualty, with the rest of the vaping industry in the government’s sights.

 

Dr. Zubair Karim, assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, was a researcher on a study that looked at Juul e-cigarettes and how they elevate the risk of thrombosis and other complications in patients.

 

Up in smoke? Vaping on the edge of banishment

 

“Thrombosis is the formation of a blood clot, either partial or complete blockage, within blood vessels, whether venous or arterial, limiting the natural flow of blood,” Karim said.

 

“There are several complications depending on where the thrombosis is located. The most serious problems include stroke, heart attack and serious breathing problems, which is called pulmonary embolism. If the patients are not treated in a timely manner, it will lead to life-threatening conditions. However, progression of the disease can be prevented by following changes in our lifestyle such as increasing physical activity, quitting smoking, losing weight, eating a balanced diet, quitting junk food and managing other health conditions.”

 

With the ban on Juul products, could this result in a ban on other companies’ e-cigarette products as well, or was there something specifically about Juul that caused their ban?

 

“This is the first steps toward the banning of the e-cigarette, i.e., Juul, where the FDA took a significant and bold step,” Karim said.

 

“Gradually, this will open the path for banning of the other e-cigarette products. There are no differences in the Juul and other products, but Juul became more popular in our young generation. Many local and state jurisdictions have recently begun enacting laws that prohibit e-cigarette usage, although some state laws with comprehensive smoke-free laws will still allow for vaping to be permitted in bars and restaurants while prohibiting e-cigarettes in other indoor places.”

 

For years, e-cigarettes and vaping devices were seen as a “safer” alternative to traditional cigarettes, but with flavors and packaging that has attracted children to the fad, efforts have been renewed to look into the possible side effects.

 

“Both smoking and vaping have similar side effects and cause serious health risks in the long run. Scientists do not fully understand the long-term health effects of electronic cigarettes, yet science indicates that they are not a safe alternative to smoking,” said Karim.

 

“In the last several years it has been observed that vaping is growing in popularity among teenagers. Moreover, e-cigarettes contain a large dose of nicotine, a substance known to slow the development of brains in fetuses, children and teens. Furthermore, vaping involves breathing in aerosol that contains several chemicals, including nicotine and flavoring through an e-cigarette or other devices. Also, the liquid present in the e-cigarettes which creates the vapor is dangerous to adults and children if they swallow, inhale, or get it on the skin.

 

Nonetheless, vaping also delivers dangerous chemicals, including diacetyl, cancer-causing chemicals, heavy metals, volatile organic compounds, and such toxic chemicals that are not generated in traditional cigarettes. In summary, long-term vaping causes similar toxic impact to overall health compared to traditional cigarettes.”

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
Product | DOJO Launches 0+6ml BLAST7K Fresh in UK in September, Retaining 2+8ml Pod Compatibility Ahead of October Per-Milliliter Vaping Duty
DOJO officially launched the BLAST7K Fresh on September 17, 2026, introducing a UK-market prefilled pod product with 6ml of e-liquid and a manufacturer-rated capacity of up to 7,000 puffs. The device features a 1000mAh rechargeable battery, the INSTA-JUICED structure and COREX BLAST dual-mesh technology, while retaining compatibility with existing BLAST pods. The launch comes less than two weeks before the UK's Vaping Products Duty takes effect on October 1. At the new duty rate, 6ml of vaping liquid would correspond to £1.32 in VPD. DOJO has not stated that the product's 6ml format was designed in response to the new duty.
Sep.20
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
BAT Expands ITC Infotech Partnership Across Poland, Romania and India to Advance AI
ITC Infotech has expanded its multi-year strategic technology partnership with British American Tobacco (BAT), providing technology services across Poland, Romania and India while continuing to support BAT's newly launched Future Capabilities Centre in India and existing technology hubs in Malaysia and Mexico. The companies said the agreement will focus on AI-enabled innovation, technology capability building and greater operational efficiency. The partnership also aligns with BAT's broader Fit2Win transformation programme, under which the group is expanding the use of external technology and business-services partners to simplify its global operating model.
Aug.13
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08